secwatch.observer — SEC 8-K summary
======================================

Issuer:     Traws Pharma, Inc. (TRAW)
CIK:        0001130598
Form:       8-K
Filed at:   2025-01-23T23:59:59+00:00
Accession:  0001104659-25-005455
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Traws Pharma completes Phase 1 studies for single-dose bird flu drug tivoxavir marboxil
--------------------------------------------------------------------------------

- Phase 1 trial showed safety, tolerability, and PK supporting dosing for H5N1 treatment and prevention.
- No significant treatment-related adverse events reported across four dose levels in healthy volunteers.
- Preclinical data showed potent inhibition of drug-resistant and highly pathogenic bird flu viruses.
- Company plans to use data to guide upcoming regulatory meetings for accelerated development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1130598/000110465925005455/0001104659-25-005455-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1130598/000110465925005455/tm253126d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-005455

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer